184 related articles for article (PubMed ID: 34540037)
21. Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease.
Wang J; Huang Z; Xue M; Huang H; Zheng X; Zhong N; Sun B
J Clin Lab Anal; 2020 Feb; 34(2):e23070. PubMed ID: 31691368
[TBL] [Abstract][Full Text] [Related]
22. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
23. The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease.
Zheng P; Zheng X; Takehiro H; Cheng ZJ; Wang J; Xue M; Lin Q; Huang Z; Huang H; Liao C; Sun B
J Transl Int Med; 2021 Sep; 9(3):212-222. PubMed ID: 34900632
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Clinical Value of KL-6 and Tumor Markers in Primary Sjögren's Syndrome Complicated with Interstitial Lung Disease.
Wei F; Zhang X; Yang S; Geng J; Xie B; Ren Y; Dai H
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568332
[TBL] [Abstract][Full Text] [Related]
25. Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway.
Zuo Y; Liu J; Xu H; Li Y; Tao R; Zhang Z
J Thorac Dis; 2022 Jun; 14(6):2089-2102. PubMed ID: 35813760
[TBL] [Abstract][Full Text] [Related]
26. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
28. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.
Wang Y; Chen S; Zheng S; Lin J; Hu S; Zhuang J; Lin Q; Xie X; Zheng K; Zhang W; Du G; Zhang G; Hoffmann-Vold AM; Matucci-Cerinic M; Furst DE
Arthritis Res Ther; 2021 Aug; 23(1):212. PubMed ID: 34391465
[TBL] [Abstract][Full Text] [Related]
29. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis.
d'Alessandro M; Bellisai F; Bergantini L; Cameli P; D'Alessandro R; Mazzei MA; Gentili F; Conticini E; Selvi E; Frediani B; Matucci-Cerinic M; Bargagli E
Eur J Clin Invest; 2021 Aug; 51(8):e13543. PubMed ID: 33759179
[TBL] [Abstract][Full Text] [Related]
31. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
[No Abstract] [Full Text] [Related]
32. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
[TBL] [Abstract][Full Text] [Related]
33. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
[TBL] [Abstract][Full Text] [Related]
34. Screening value of lung ultrasound in connective tissue disease related interstitial lung disease.
Huang Y; Liu T; Huang S; Qiu L; Luo F; Yin G; Xie Q
Heart Lung; 2023; 57():110-116. PubMed ID: 36182861
[TBL] [Abstract][Full Text] [Related]
35. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
[TBL] [Abstract][Full Text] [Related]
36. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].
Zhu C; Zhao YB; Kong LF; Li ZH; Kang J
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):93-7. PubMed ID: 26879611
[TBL] [Abstract][Full Text] [Related]
37. KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.
Chiu YH; Chu CC; Lu CC; Liu FC; Tang SE; Chu SJ; Kuo SY; Chen HC
J Inflamm Res; 2022; 15():2255-2262. PubMed ID: 35422651
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease.
Nobashi T; Kubo T; Nakamoto Y; Handa T; Koyasu S; Ishimori T; Mishima M; Togashi K
J Nucl Med; 2016 Dec; 57(12):1899-1904. PubMed ID: 27339874
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.
Kamiya Y; Fujisawa T; Kono M; Nakamura H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Sumikawa H; Johkoh T; Yasui H; Hozumi H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
Respir Med; 2019 Nov; 159():105811. PubMed ID: 31710871
[TBL] [Abstract][Full Text] [Related]
40. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
